Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + zanubrutinib vs placebo + zanubrutinib in relapsed/refractory mantle cell lymphoma
CTR20250207Phase 3Active
- Sponsor
- BeiGene
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sonrotoclax in mantle cell lymphoma (MCL), sponsored by BeiGene. Started Mar 2025; status: active.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20250207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250207.